NO971349L - Anvendelse av aromatiske inhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn - Google Patents

Anvendelse av aromatiske inhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn

Info

Publication number
NO971349L
NO971349L NO971349A NO971349A NO971349L NO 971349 L NO971349 L NO 971349L NO 971349 A NO971349 A NO 971349A NO 971349 A NO971349 A NO 971349A NO 971349 L NO971349 L NO 971349L
Authority
NO
Norway
Prior art keywords
men
pct
androgen deficiency
medicament
manufacture
Prior art date
Application number
NO971349A
Other languages
English (en)
Norwegian (no)
Other versions
NO971349D0 (no
Inventor
Albert Radlmaier
Ursula-Friederike Habenicht
Friedmund Neumann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6529877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO971349(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO971349D0 publication Critical patent/NO971349D0/no
Publication of NO971349L publication Critical patent/NO971349L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
NO971349A 1994-09-22 1997-03-21 Anvendelse av aromatiske inhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn NO971349L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4435368A DE4435368A1 (de) 1994-09-22 1994-09-22 Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
PCT/EP1995/003733 WO1996009057A1 (de) 1994-09-22 1995-09-22 Verwendung von aromatasehemmern zur herstellung eines arzneimittels zur behandlung eines relativen androgenmangels beim mann

Publications (2)

Publication Number Publication Date
NO971349D0 NO971349D0 (no) 1997-03-21
NO971349L true NO971349L (no) 1997-05-16

Family

ID=6529877

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971349A NO971349L (no) 1994-09-22 1997-03-21 Anvendelse av aromatiske inhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn

Country Status (21)

Country Link
US (1) US5861389A (cs)
EP (1) EP0782450B1 (cs)
JP (1) JPH10505848A (cs)
KR (1) KR100387345B1 (cs)
CN (1) CN1104243C (cs)
AT (1) ATE241989T1 (cs)
AU (1) AU707997B2 (cs)
BR (1) BR9509155A (cs)
CA (1) CA2200195C (cs)
CZ (1) CZ76097A3 (cs)
DE (2) DE4435368A1 (cs)
DK (1) DK0782450T3 (cs)
ES (1) ES2199255T3 (cs)
FI (1) FI971207L (cs)
HU (1) HUT76981A (cs)
MX (1) MX9702170A (cs)
NO (1) NO971349L (cs)
PL (1) PL182909B1 (cs)
PT (1) PT782450E (cs)
SK (1) SK36397A3 (cs)
WO (1) WO1996009057A1 (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19610645A1 (de) * 1996-03-06 1997-09-11 Schering Ag Kombination von Dehydroepiandrosteron und Aromatasehemmern und Verwendung dieser Kombination zur Herstellung eines Arzeimittels zur Behandlung eines relativen und absoluten Androgenmangels beim Mann
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2001091744A1 (en) 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US6607755B2 (en) * 2001-06-21 2003-08-19 Michael Donald Farley Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
CN1289075C (zh) * 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
PT1463497E (pt) * 2001-12-06 2011-12-20 Gtx Inc Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios
US6586417B1 (en) 2002-04-22 2003-07-01 Nutrisport Pharmacal, Inc. Ester and ether derivatives of 4-hydroxy 4-androstene-3,17-dione and a method for the regulation of athletic function in humans
WO2004064813A1 (en) * 2003-01-13 2004-08-05 Michael Donald Farley Improvements in or relating to anti-aromatase composition
WO2004064814A1 (en) * 2003-01-13 2004-08-05 Michael Donald Farley Improvements in or relating to anti-aromatase composition
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
EP1776098A1 (en) * 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
WO2006084153A2 (en) * 2005-02-04 2006-08-10 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
NZ560551A (en) * 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
JP5123935B2 (ja) 2006-05-22 2013-01-23 ホルモス メディカル リミテッド 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
CN102335219A (zh) * 2007-11-21 2012-02-01 客乐谐制药株式会社 芳香酶抑制剂
US20090215738A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Prevention and treatment of an increase in cardiovascular risk, adverse cardiovascular events, infertility, and adverse psychological effects after androgen or gnrh analogue intake
CA2673461C (en) * 2009-08-07 2011-07-26 Bruce W. Kneller 5.alpha.-androstane-3,6,17-trione (kneller's trione) and methods of use therefor
US20090306031A1 (en) * 2009-08-07 2009-12-10 Kneller Bruce W 5alpha-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013020215A1 (en) * 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
SI2753312T1 (sl) * 2011-09-08 2017-10-30 Mereo Biopharma 2 Limited Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni
CN102641502A (zh) * 2012-04-25 2012-08-22 中国农业大学 芳香酶抑制剂的新用途
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289762A (en) * 1980-06-27 1981-09-15 Merrell Dow Pharmaceuticals Inc. 10-(1,2-Propadienyl) steroids as irreversible aromatase inhibitors
US4322416A (en) * 1980-06-27 1982-03-30 Merrell Dow Pharmaceuticals Inc. 10-Alkynyl steroids
DE3362176D1 (en) * 1982-07-14 1986-03-27 Akzo Nv Novel 19-thio-androstane derivatives
DE3322285A1 (de) * 1983-06-18 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3539244A1 (de) * 1985-11-01 1987-05-07 Schering Ag 1-methyl-15(alpha)-alkyl-androsta- 1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
GB8531745D0 (en) * 1985-12-24 1986-02-05 Erba Farmitalia 10beta-alkynyl-4-9(11)-estradiene derivatives
GB8615092D0 (en) * 1986-06-20 1986-07-23 Erba Farmitalia Androst-4-ene-317-diones
DE3705990A1 (de) * 1987-02-20 1988-09-01 Schering Ag 1-methyl-15(alpha)-(1-oxyalkyl)-androsta-1,4-dien- 3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3926365A1 (de) * 1989-08-04 1991-02-07 Schering Ag Cycloalkylenazole, verfahren zu deren herstellung, pharmazeutische praeparate, die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln
GB9226620D0 (en) * 1992-12-21 1993-02-17 Fujisawa Pharmaceutical Co A new compound fr 901537,production thereof and use thereof

Also Published As

Publication number Publication date
EP0782450B1 (de) 2003-06-04
KR100387345B1 (ko) 2003-08-30
AU3651895A (en) 1996-04-09
DK0782450T3 (da) 2003-08-18
CN1158570A (zh) 1997-09-03
WO1996009057A1 (de) 1996-03-28
DE4435368A1 (de) 1996-03-28
EP0782450A1 (de) 1997-07-09
PL319299A1 (en) 1997-08-04
DE59510714D1 (de) 2003-07-10
MX9702170A (es) 1998-04-30
CZ76097A3 (en) 1997-07-16
US5861389A (en) 1999-01-19
JPH10505848A (ja) 1998-06-09
FI971207A7 (fi) 1997-03-21
CA2200195A1 (en) 1996-03-28
NO971349D0 (no) 1997-03-21
PL182909B1 (pl) 2002-04-30
AU707997B2 (en) 1999-07-29
BR9509155A (pt) 1997-10-14
SK36397A3 (en) 1997-08-06
ATE241989T1 (de) 2003-06-15
FI971207A0 (fi) 1997-03-21
KR970706002A (ko) 1997-11-03
PT782450E (pt) 2003-09-30
HUT76981A (hu) 1998-01-28
FI971207L (fi) 1997-03-21
CN1104243C (zh) 2003-04-02
CA2200195C (en) 2008-04-22
ES2199255T3 (es) 2004-02-16

Similar Documents

Publication Publication Date Title
NO971349D0 (no) Anvendelse av aromataseinhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn
Labrie et al. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist
NO20003546L (no) Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse
Perlroth et al. Oral contraceptive agents and the management of acute intermittent porphyria
EP1319404A3 (de) Mittel zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
GR3036745T3 (en) New pharmaceutical preparation for pain management
CA2467222A1 (en) Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
BG105302A (en) Means for improving cognition
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
Silberstein et al. Migraine, menopause and hormonal replacement therapy
HUP9901505A2 (hu) Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására
Mössner Is there a place for pancreatic enzymes in the treatment of pain in chronic pancreatitis?
GR3035358T3 (en) Use of cyclooxygenase inhibitors for the manufacture of a medicament for enhancing uterine blood perfusion
BR0208968A (pt) Inibição de aromatase para aumentar a reprodução assistida
WO2003032961A3 (en) Methods for preventing and treating bone loss with steroid compounds
Tudyka et al. Gallstone recurrence after successful dissolution therapy
WO2006041939A3 (en) Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus
BR0208920A (pt) Inibidor de aromatase em dose única para tratamento de infertilidade
EP1240901A4 (en) MEDICINAL COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF DISEASES BASED ON ABNORMAL BLOOD COAGULATION
McKeon Estrogen replacement therapy: Current guidelines for education and counseling
DK0648117T3 (da) Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser
AU2003285426A8 (en) Use of tenatoprazole for the treatment of gastroesophageal reflux
EP0968717B1 (fr) Préparation sous forme galénique simple visant à limiter les effects induits durant la ménopause et postérieurement et traitement avec cette préparation